Dr. Desai on selection criteria for the ideal candidate for bladder preservation surgery

Results from CREST will be presented at an upcoming medical conference.

In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.

9MW2821 was previously awarded a breakthrough therapy designation as a monotherapy for locally advanced or metastatic urothelial carcinoma.

“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.

The NMPA’s approval was supported by data from the phase 3 EV-302 trial.

The J-code became effective on January 1, 2025.